Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome.

We suggest that fondaparinux may be used for TAPS when VKA is not appropriate. Thrombotic recurrence was infrequent, and the number of major bleeding events appeared comparable to conventional therapies.